Oculis’ acute optic neuritis therapy trial meets primary endpoint
The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.
The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.
After disappointing Phase IIb results for avicursen last month, Percheron will adopt a three-pronged business strategy.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
2024: record year for AI trials
First blood-stage malaria vaccine ‘a much-needed addition’ – analyst